Prostate Cancer Clinical Trial
Post-prostatectomy Radiation Therapy–Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
Summary
The primary purpose of this study is to compare the quality of life (QOL) reported by prostate cancer patients 2 years after treatment with ultra-hypofractionated post-prostatectomy radiation therapy (also known as stereotactic body radiation therapy [SBRT]) versus the self-reported QOL of those treated with moderately hypo-fractionated post-prostatectomy radiation (a current standard of care option).
Full Description
Conventional or moderately hypo-fractionated radiation therapy are the current standard of care treatment options for men receiving post-prostatectomy radiation therapy. These treatment regimens typically span 4-8 weeks, representing a high burden of therapy, which may result in decreased utilization of salvage radiotherapy, the only potentially curable treatment for men with relapsed disease following prostatectomy. Ultra-hypofractionated radiation therapy (also known as stereotactic body radiation therapy [SBRT]) would decrease the total number of treatments to 5, delivered over 2 weeks, which would greatly reduce treatment burden.
Eligibility Criteria
Inclusion Criteria:
Men age ≥ 18 with histologically confirmed prostate cancer after radical prostatectomy with a PSA ≥ 0.1 ng/mL
Interval between prostatectomy and planned radiation therapy start date ≥ 6 months
KPS ≥ 70
Patients with equivocal pelvic lymph nodes on imaging are eligible if the nodes are ≤ 1.5 cm in the short axis (equivocal evidence of metastatic disease outside of the pelvis on standard imaging requires documented negative biopsy)
Ability to complete the EPIC-26 quality of life questionnaire
Ability to obtain tissue from radical prostatectomy specimen for review by Michigan Medicine Pathology
Ability to understand and the willingness to sign a written informed consent.
Exclusion Criteria:
Prior history of pelvic radiation therapy
History of moderate/severe or active Crohn's disease or ulcerative colitis
History of bladder neck or urethral stricture
Evidence of distant metastatic disease or nodal involvement beyond the common iliac vessels
Initiation of androgen deprivation therapy with a LHRH / GnRH agonist or antagonist greater than 6 months prior to enrollment or receipt of any non-LHRH / GnRH agonist or antagonist androgen deprivation or anti-androgen therapy
History of another invasive malignancy within the previous 3 years except for adequately treated squamous or basal cell skin cancer
Any condition that in the opinion of the investigator would preclude participation in this study
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Ann Arbor Michigan, 98107, United States More Info
Principal Investigator
How clear is this clinincal trial information?